 BetterLife Pharma Inc CSE:BETR OTCQB:BETRF FRA:NPAU issued a progress update on its drug pipeline for the treatment of mental health disorders, which includes a non-hallucinogenic LSD compound. TD-0148A is a second-generation LSD derivative molecule that has been synthesized using BetterLifes patented manufacturing process. 